Bioventus Inc. (NYSE:BVS) Shares Sold by Olympiad Research LP

Olympiad Research LP reduced its position in Bioventus Inc. (NYSE:BVS) by 34.8% in the 4th quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 13,697 shares of the company’s stock after selling 7,317 shares during the quarter. Olympiad Research LP’s holdings in Bioventus were worth $144,000 at the end of the most recent reporting period.

A number of other hedge funds have also modified their holdings of BVS. Virtus Fund Advisers LLC acquired a new stake in shares of Bioventus in the third quarter valued at approximately $42,000. Quest Partners LLC purchased a new position in Bioventus in the third quarter worth approximately $51,000. Quarry LP acquired a new stake in Bioventus during the third quarter worth $59,000. Covestor Ltd purchased a new stake in Bioventus in the third quarter valued at $69,000. Finally, CWM LLC acquired a new position in shares of Bioventus in the 3rd quarter valued at $89,000. 62.94% of the stock is currently owned by institutional investors and hedge funds.

Insider Activity at Bioventus

In other Bioventus news, SVP Anthony D’adamio sold 4,380 shares of the business’s stock in a transaction on Tuesday, February 18th. The shares were sold at an average price of $10.19, for a total value of $44,632.20. Following the completion of the transaction, the senior vice president now owns 118,178 shares in the company, valued at $1,204,233.82. The trade was a 3.57 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, CEO Robert E. Claypoole sold 28,786 shares of the company’s stock in a transaction on Monday, January 13th. The stock was sold at an average price of $9.10, for a total value of $261,952.60. Following the sale, the chief executive officer now directly owns 64,964 shares in the company, valued at $591,172.40. This represents a 30.71 % decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 52,932 shares of company stock worth $512,511. 32.90% of the stock is currently owned by company insiders.

Wall Street Analysts Forecast Growth

A number of analysts recently issued reports on the company. JPMorgan Chase & Co. raised Bioventus from an “underweight” rating to a “neutral” rating and raised their price objective for the stock from $12.00 to $13.00 in a research report on Tuesday, December 17th. Canaccord Genuity Group lifted their price target on shares of Bioventus from $12.00 to $15.00 and gave the company a “buy” rating in a research report on Wednesday, November 6th.

Bioventus Stock Up 0.6 %

NYSE:BVS opened at $10.01 on Monday. Bioventus Inc. has a 52 week low of $3.90 and a 52 week high of $14.38. The company has a quick ratio of 0.99, a current ratio of 1.41 and a debt-to-equity ratio of 1.85. The stock’s fifty day moving average is $10.32 and its two-hundred day moving average is $10.89. The stock has a market capitalization of $812.31 million, a price-to-earnings ratio of -16.41 and a beta of 0.85.

About Bioventus

Bioventus Inc, a medical device company, focuses on developing and commercializing treatments that engage and enhance the body's natural healing process in the United States and internationally. The company's product portfolio includes pain treatments, which comprise non-surgical pain injection therapies, as well as peripheral nerve stimulation products, such as Durolane, GELSYN-3, and SUPARTZ for the treatment of knee osteoarthritis and Stimrouter to treat chronic peripheral pain.